|Table of Contents|

Expression of forkhead box protein 3(Foxp3) in gastric stromal tumors and its clinicopathological significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

2023 13
Research Field:
Publishing date:


Expression of forkhead box protein 3(Foxp3) in gastric stromal tumors and its clinicopathological significance
WU ZhaoyingXIE HaoZOU JunweiZHANG LeiHUANG Yong
Department of Gastrointestinal Surgery,The Second Affiliated Hospital of Wannan Medical College,Anhui Wuhu 241000,China.
Foxp3gastric GISTsclinicopathological factorsprognosis
Objective:To assess the expression of Foxp3 in gastric GISTs tissues using immunohistochemistry(IHC) techniques and to analyze whether Foxp3 expression is associated with the clinicopathological factors and prognosis of patients with this disease.Methods:Specimens from 96 patients with gastric GISTs were collected and the expression of Foxp3 in tumor and adjacent normal tissues were detected by immunohistochemistry.The association between expression level of Foxp3 with the clinicopathological factors and prognosis of patients were analyzed,respectively.Results:Foxp3 was high-expression in gastric GISTs compared with adjacent normal tissues.Foxp3 expression was positively associated with tumor risk classification,mitotic index,tumor size,tumor necrosis and imatinib administration.Univariate analysis showed that the high expression of Foxp3 was inversely correlated with the overall survival,furthermore,multivariate analysis showed that Foxp3 was an independent prognostic factor for patients with gastric stromal tumor.Conclusion:These results of this study suggested that the high expressions of Foxp3 was associated with a poor prognosis,which may be a potential diagnostic marker and therapeutic target for gastric GISTs.


[1]NEGREANU LM,ASSOR P,MATEESCU B.Interstitial cells of Cajal in the gut-a gastroenterologist's point of view[J].World Gournal of Gastroenterology,2008,14(41):6285-6288.
[2]REICHARDT P,SCHLEMMER M,DELGADO PEREZ JR,et al.Safety of imatinib mesylate in a multicenter expanded access program in adult patipnts with gastrointestinal stromal tumors in the adjuvant setting[J].Oncol Res Treat,2019,42(12):629-635.
[3]ANTONANA-VILDOSOLA A,ZANETTI SR,PALAZON A.Enabling CAR-T cells for solid tumors:Rage against the suppressive tumor microenvironment[J].Int Rev Cell Mol Biol,2022,370:123-147.
[4]RAUGH A,ALLARD D,BETTINI M.Nature vs nurture:FOXP3,genetics,and tissue environment shape treg function[J].Front Immunol,2022,13:911151.
[5]GODA N,NAKASHIMA C,NAGAMINE I,et al.The effect of intratumoral interrelation among Foxp3+ regulatory T cells on treatment response and survival in triple-negative breast cancer[J].Cancers(Basel),2022,14(9):2138.
[6]PU JT,ZHANG T,HE KM,et al.Transient receptor potential vanilloid 4 promotes the growth of non-small cell lung cancer by regulating Foxp3[J].Acta Biochim Pol,2022, 69(1):51-57.
[7]FATTAHI S,KARIMI M,GHATREH-SAMANI M,et al.Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer[J].Int J Exp Pathol,2021,102(6):249-259.
[8]YAN B,XIONG J,YE Q,et al.Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3+ T regulatory cells in colorectal cancer[J].BMC Gastroenterol,2022,22(1):122.
[9]XU QR,TANG J,LIAO HY,et al.Long non-coding RNA MEG3 mediates the miR-149-3p/Foxp3 axis by reducing p53 ubiquitination to exert a suppressive effect on regulatory T cell differentiation and immune escape in esophageal cancer[J].J Transl Med,2021,19(1):264.
[10]ZHANG HY,SUN H.Up-regulation of Foxp3 inhibits cell proliferation,migration and invasion in epithelial ovarian cancer[J].Cancer Lett,2010,287(1):91-97.
[11]JOENSUU H.Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J].Hum Pathol,2008,39(10):1411-1419.
[12]CHEN S,SANG K,CHEN W,et al.Risk factors and prognostic analysis of gastrointestinal stromal tumor recurrence-metastasis[J].Comput Math Methods Med,2022,2022:1127146.
[13]ANTONESCU CR,DEMATTEO RP.CCR 20th anniversary commentary:A genetic mechanism of imatinib resistance in gastrointestinal stromal tumor-where are we a decade later[J].Clin Cancer Res,2015,21(15):3363-3365.
[14]BANERJEE S,YOON H,TING S,et al.KIT low cells mediate imatinib resistance in gastrointestinal stromal tumor[J].Mol Cancer Ther,2021,20(10):2035-2048.
[15]DU J,WANG Q,YANG S,et al.Foxp3 exon 2 controls Treg stability and autoimmunity[J].Sci Immunol,2022,7(72):eabo5407.
[16]EBERT LM,TAN BS,BROWNING J,et al.The regulatory T cell-associated transcription factor Foxp3 is expressed by tumor cells[J].Cancer Res,2008,68(8):3001-3009.
[17]KIM M,GRIMMIG T,GRIMM M,et al.Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer[J].PLoS One,2013,8(1):e53630.
[18]LOPES LF,GUEMBAROVSKI RL,GUEMBAROVSKI AL,et al.Foxp3 transcription factor:a candidate marker for susceptibility and prognosis in triple negative breast cancer[J].Biomed Res Int,2014,2014:341654.
[19]FRATTINI V,PISATI F,SPERANZA MC,et al.Foxp3,a novel glioblastoma oncosuppressor,affects proliferation and migration[J].Oncotarget,2012,3(10):1146-1157.
[20]TRIULZI T,TAGLIABUE E,BALSARI A,et al.Foxp3 expression in tumor cells and implications for cancer progression[J].J Cell Physiol,2013,228(1):30-35.
[21]SARKAR T,DHAR S,CHAKRABORTY D,et al.Foxp3/HAT1 axis controls treg infiltration in the tumor microenvironment by inducing CCR4 expression in breast cancer[J].Front Immunol,2022,13:740588.
[22]SHAN Y,ZHANG B,CHEN L,et al.Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells[J].Anticancer Drugs,2023,34(1):73-80.
[23]HATIPOGLU E,DEMIRYAS S.Gastrointestinal stromal tumors:16 years' experience within a university hospital[J].Rev Esp Enferm Dig,2018,110(6):358-364.


Last Update: 2023-05-31